R&D News | pharmaphorum

News

Celltrion closes in on COVID-19 antibody market after trial ...

South Korea’s Celltrion has announced encouraging top-line results for its potential antibody therapy for COVID-19, with the first part of a phase 2/3 trial showing it could cut recovery ti

News

Closeup of X-ray photography of human brain

Could Lilly’s donanemab readout in Alzheimer's boost Biogen’...

When Eli Lilly reported results for donanemab in Alzheimer’s disease earlier this week it was hailed as a rare win for the amyloid hypothesis, although there’s no shortage of candidates tha

News

Study says COVID-19 infection provides immunity, but people ...

Previous COVID-19 infection provides some immunity for at least five months, but people may still carry and transmit the virus, according to a study by Public Health England.

News

Synairgen starts dosing inhaled COVID-19 drug in phase 3 tri...

UK biotech Synairgen is pushing ahead with a phase 3 trial of SNG001 in hospitalised COVID-19

News

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBi...

ImmunityBio has licensed technology underpinning a COVID-19 vaccine that could be administered orally rather than by injection from UK biotech iosBio.

News

RNAi biotech Atalanta debuts with $110m plus Biogen and Roch...

US biotech Atalanta Therapeutics has come out of stealth mode backed with $110m from Biogen and Roche, who have also signed separate partnerships to develop new therapies for neurological d

Celltrion closes in on COVID-19 antibody market after trial ...

Could Lilly’s donanemab readout in Alzheimer's boost Biogen’...

Study says COVID-19 infection provides immunity, but people ...

Synairgen starts dosing inhaled COVID-19 drug in phase 3 tri...

Oral COVID-19 vaccine beckons, as ImmunityBio licenses iosBi...

RNAi biotech Atalanta debuts with $110m plus Biogen and Roch...

UCB buys cell therapy biotech Candid for $2bn upfront

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks